Cancer
Conditions
Brief summary
Participants will be testing with the home monitoring device over the course of their treatment. They are to self-test on days where they are due to be going into hospital for their routine pre-treatment blood tests. Participants will be asked to fill in interim questionnaires and a final questionnaire to answer the study objectives.
Interventions
DEVICEEntia Liberty
Home monitoring blood analyser
Sponsors
Entia Ltd
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 * Adequate English language skills (not requiring a translator) to participate in participant training and use the Liberty device * Patients willing and able to perform capillary blood self-testing at the same frequency as routine full blood count monitoring * Patients capable of providing informed consent before attending training * Patients able to attend a 1-hour virtual training session within 2 weeks of joining the study * Patients with a home Wi-Fi network or with adequate coverage at home via a 4G network * Patients with access to a laptop or smartphone to facilitate training * Patients with a diagnosis of ovarian or breast cancer * Patients whose HCPs can confirm are undergoing systemic anti-cancer treatments within two weeks of enrolment, with treatment expected to continue for at least two cycles
Exclusion criteria
* Patients with haematological malignancies * Patients with eyesight or hearing limitations or other disabilities that preclude the use of the Liberty device or participation in training unless they have a nominated caregiver who is capable of assisting with each test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess patient preference for the Liberty self-testing pathway as compared to standard of care. | 12 months | Patients will undergo the study procedures without change to their current pathway, at the end of the study, patients will compare the interventions via a SURVEY. The investigators will measure the success of the comparison by the % of patients who have chosen the investigators' product over the standard of care (4-5 rating out of 5). |
Countries
United Kingdom
Outcome results
None listed